Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2020; 66(6): 41-48


Effect of avandamet on conditioned food reflex in rats of different age groups

V.A. Gorbachenko, Zh.O. Kruchenko, E.A. Lukyanetz

    O.O. Bogomoletz Institute of Physiology, NAS Ukraine, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz66.06.041

Abstract

The prevalence of Alzheimer’s disease (AD) is increasing in the absence of truly effective treatments. The recently discovered causal link between AD and type 2 diabetes mellitus (T2DM) (non-insulin-dependent diabetes mellitus) suggests that an increase in insulin receptor resistance may affect brain aging and lead to AD. In our experiments, we tested Avandamet (AVD), the antidiabetic drug used for the treatment of T2DM, on temporary parameters of conditioning food reflex in rats. We measured the individual components of the sensorimotor reaction (SMR) of rats, which reflect CNS’s functional state. Important tha7t rosiglitazone is the main component of AVD. It acts by activating the nuclear peroxisome proliferator-activated receptor (PPAR) gamma. Our data showed that this drug influences the brain function of both young and old rats. It is proved that AVD affects the CNS of rats by increasing their excitability. Considering the obtained data from the point of view of AD, the time parameter, which changed more significantly in old rats, was responsible for analyzing the situation and speed of action. Under AVD’s influence, old rats became more agile and had increased motor activity, also the success of rats in performing a conditioned reflex was increased. Thus, the drug AVD and its active component rosiglitazone can be perspective for its testing in AD treatment.

Keywords: Alzheimer’s disease; avandamet; behavior; conditioning reflex; food reflex; rats; PPAR; rosiglitazone

References

  1. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol. 2011;71(3):365-76. CrossRef PubMed PubMedCentral
  2. McIntyre RS, Soczynska JK, Lewis GF, MacQueen GM, Konarski JZ, Kennedy SH. Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opinion Pharmacother. 2006;7(10):1305-21. CrossRef PubMed
  3. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004;53(2):474. CrossRef PubMed
  4. Cao B, Rosenblat JD, Brietzke E, Park C, Lee Y, Musial N, et al. Comparative efficacy and acceptability of antidiabetic agents for Alzheimer's disease and mild cognitive impairment: A systematic review and network meta-analysis. Diabetes, Obesity Metab. 2018;20(10):2467-71. CrossRef PubMed
  5. Pilipenko V, Narbute K, Pupure J, Langrate IK, Muceniece R, Kluša V. Neuroprotective potential of antihyperglycemic drug metformin in streptozocin-induced rat model of sporadic Alzheimer's disease. Eur J Pharmacol. 2020:173290. CrossRef PubMed
  6. Li H, Wu J, Zhu L, Sha L, Yang S, Wei J, et al. Insulin degrading enzyme contributes to the pathology in a mixed model of type 2 diabetes and Alzheimer's disease: possible mechanisms of IDE in T2D and AD. Biosci Reports. 2018;38(1). CrossRef PubMed PubMedCentral
  7. de Nazareth AM. Type 2 diabetes mellitus in the pathophysiology of Alzheimer's disease. Dement Neuropsychol. 2017;11(2):105-13. CrossRef PubMed PubMedCentral
  8. Tumminia A, Vinciguerra F, Parisi M, Frittitta L. Type 2 diabetes mellitus and Alzheimer's disease: Role of insulin signalling and therapeutic implications. Int J Mol Sci. 2018;19(11):3306. CrossRef PubMed PubMedCentral
  9. Mittal K, Katare DP. Shared links between type 2 diabetes mellitus and Alzheimer's disease: A review. Diabetes Metablic Syndrome: Clinical Research & Reviews. 2016;10(2, Suppl 1):S144-S9. CrossRef PubMed
  10. Chatterjee S, Mudher A. Alzheimer's disease and type 2 diabetes: A critical assessment of the shared pathological traits. Front Neurosci. 2018;12:383. CrossRef PubMed PubMedCentral
  11. Caberlotto L, Nguyen TP, Lauria M, Priami C, Rimondini R, Maioli S, et al. Cross-disease analysis of Alzheimer's disease and type-2 diabetes highlights the role of autophagy in the pathophysiology of two highly comorbid diseases. Sci Reports. 2019;9(1):3965. CrossRef PubMed PubMedCentral
  12. Kamal MA, Priyamvada S, Anbazhagan AN, Jabir NR, Tabrez S, Greig NH. Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation. CNS Neurol Disord Drug Targets. 2014;13(2):338-46. CrossRef PubMed PubMedCentral
  13. Sarathlal K CS, Kakoty V, Marathe S, Chitkara D, Taliyan R. Exploring the neuroprotective potential of rosiglitazone embedded nanocarrier system on streptozotocin induced mice model of Alzheimer's disease. Neurotoxic Res. 2020.
  14. Denner LA, Rodriguez-Rivera J, Haidacher SJ, Jahrling JB, Carmical JR, Hernandez CM, et al. Cognitive enhancement with rosiglitazone links the hippocampal PPARγ and ERK MAPK signaling pathways. J Neurosci: the official journal of the Society for Neuroscience. 2012;32(47):16725-35a. CrossRef PubMed PubMedCentral
  15. Xu S, Guan Q, Wang C, Wei X, Chen X, Zheng B, et al. Rosiglitazone prevents the memory deficits induced by amyloid-beta oligomers via inhibition of inflammatory responses. Neurosci Lett. 2014;578:7-11. CrossRef PubMed
  16. Gorbachenko V, Chereda I, Vrublevsky S, Kruchenko J, Lukyanetz E. Development and testing of the experimental system for registration of food reflex in rats. Bull Taras Shevchenko Natl Univ Kyiv Ser: Radiophysics and Electronics. 2014;1/2(21/22):31-3.
  17. Gorbachenko VA, Kruchenko JO, Chereda IS, Lukyanetz EA. Measurements of the time parameters of conditioned food reflex in rats under memantin treatment with using of automatic registration system. Bull Taras Shevchenko Natl Univ KyivSer: Radiophysics and Electronics. 2015;1(23):23-6.
  18. Kravenska EV, Ganzha VV, Yavorskaya EN, Lukyanetz EA. Effect of cyclosporin A on the viability of hippocampal cells cultured under conditions of modeling of Alzheimers disease. Neurophysiology. 2016;48(4):246-51. CrossRef
  19. Kravenska Y, Nieznanska H, Nieznanski K, Lukyanetz E, Szewczyk A, Koprowski P. The monomers, oligomers, and fibrils of amyloid-β inhibit the activity of mitoBKCa channels by a membrane-mediated mechanism. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2020;1862(9):183337. CrossRef PubMed
  20. Kostiuk OP, Korol T, Korol SV, Romanenko SV, Pinchenko VO, Kostiuk PH. [Alteration of calcium signaling as one of the mechanisms of Alzheimer's disease and diabetic polyneuropathy]. Fiziol Zh (Kiev, Ukraine: 1994). 2010;56(4):130-8. CrossRef
  21. Korol T, Kostiuk OP, Kostiuk PH. [Effect of beta-amyloid protein on calcium channels in plasma membranes of cultured hippocampal neurons]. Fiziol Zh (Kiev, Ukraine:1994). 2009;55(4):10-6. CrossRef
  22. Kruchenko ZA, Gorbachenko VA, Chereda IS, Lukyanetz EA. Effect of memantine on motor behavioral phenomena in rats of different ages. Neurophysiology. 2014;46(5):448-51. CrossRef
  23. Tyshchenko Y, Lukyanetz EA. Effects of memantine on behavioral indices of rats in the open field. Neurophysiology. 2017;49(6):453-7. CrossRef
  24. DiTacchio KA, Heinemann SF, Dziewczapolski G. Metformin treatment alters memory function in a mouse model of Alzheimer's disease. J Alzheimers Dis. 2015;44(1):43-8. CrossRef PubMed
  25. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. J Adv Pharm Technol Res. 2011;2(4):236-40. CrossRef PubMed PubMedCentral
  26. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med. 2002;53:409-35. CrossRef PubMed
  27. Nierenberg AA, Ghaznavi SA, Sande Mathias I, Ellard KK, Janos JA, Sylvia LG. Peroxisome Proliferatoractivated receptor gamma coactivator-1 alpha as a novel target for bipolar disorder and other neuropsychiatric disorders. Biol Psychiat. 2018;83(9):761-9. CrossRef PubMed

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2021.